Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock Split
July 05 2022 - 7:00AM
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage,
biopharmaceutical company dedicated to developing and
commercializing first-in-class, oral enzyme therapeutics to treat
patients with rare and severe metabolic and kidney disorders, today
announced that it has rescheduled its special meeting, which was
scheduled for July 5, 2022, to, among other things, consider and
vote on a proposed amendment to its amended and restated
certificate of incorporation, as amended, in order to effect a
reverse stock split of its issued and outstanding common stock.
The date of the rescheduled special meeting, and
the new record date for determining the Allena stockholders
entitled to vote thereat, will be determined in the near future,
and will be will be included in supplemental proxy materials to be
filed with the SEC and distributed to stockholders promptly after
the new record date.
About Allena Pharmaceuticals,
Inc.
Allena Pharmaceuticals, Inc. is a
biopharmaceutical company dedicated to discovering, developing and
commercializing first-in-class, oral biologic therapeutics to treat
patients with rare and severe metabolic and kidney disorders.
Additional Information and Where to Find
It
In connection with the special meeting described
above the Company filed a definitive proxy statement with the
Securities and Exchange Commission on May 24, 2022 and in
connection with the rescheduled meeting the Company will file with
the Securities and Exchange Commission a supplement to the
definitive proxy statement. This press release does not contain all
the information that should be considered concerning the matters to
be considered at the special meeting, including the proposed
reverse stock split, and is not intended to form the basis of any
investment decision or any other decision in respect of such
matters.
The Company’s stockholders and other interested
persons are advised to read the definitive proxy statement and,
when available, the proxy supplement, and any amendments thereto,
and any other documents filed in connection with the matters to be
considered at the special meeting, including the proposed reverse
stock split, as these materials will contain important information
about the Company and such matters. The Company’s stockholders will
also be able to obtain copies of these documents filed with the
SEC, without charge, once available, at the SEC’s website at
www.sec.gov, or by directing a request to the Company’s corporate
secretary /o Allena Pharmaceuticals, Inc., One Newton Executive
Park, Suite 202, Newton, MA 02462.
Appointment of Proxy Solicitor &
Participants in Solicitation
The Company has engaged Saratoga Proxy
Consulting LLC (“Saratoga”) to assist us with the solicitation of
proxies in connection with the special meeting. We expect to pay
Saratoga a fee of $25,000, plus reimbursement for certain expenses
related to its services.
The Company and its directors and executive
officers may also be deemed participants in the solicitation of
proxies from the Company’s stockholders with respect to the special
meeting. A list of the names of those directors and executive
officers and a description of their interests in the Company is
contained in the Company’s Annual Report for the year ended
December 31, 2021 on Form 10-K, as amended, which was filed with
the SEC and is available free of charge at the SEC’s web site at
www.sec.gov. To the extent such holdings of the Company’s
securities may have changed since that time, such changes have been
or will be reflected on Statements of Change in Ownership on Form 4
filed with the SEC. Additional information regarding the interests
of such participants will be contained in the definitive proxy
statement, proxy supplement and any amendments thereto and any
other documents filed in connection with the rescheduled special
meeting when available.
Forward Looking Statements
Certain information contained in this press
release includes "forward-looking statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including
statements related to the rescheduled special meeting. We may, in
some cases, use terms such as "predicts," "believes," "potential,"
"continue," "anticipates," "estimates," "expects," "plans,"
"intends," "may," "could," “might," "will," "should" or other words
that convey uncertainty of the future events or outcomes to
identify these forward-looking statements. Our forward-looking
statements are based on current beliefs and expectations of our
management team that involve risks, potential changes in
circumstances, assumptions, and uncertainties. Any or all of the
forward-looking statements may turn out to be wrong or be affected
by inaccurate assumptions we might make or by known or unknown
risks and uncertainties as a result of various important factors,
including the uncertainties related to market conditions and the
completion of the offering on the anticipated terms or at all, the
satisfaction of customary closing conditions related to the
registered direct offering and various other factors. For a more
detailed description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to our
business in general, please refer to our most recent Annual Report
on Form 10-K and Quarterly Report on Form 10-Q. You are cautioned
not to place undue reliance on these forward-looking statements,
which are made only as of the date of this press release. We
undertake no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstances.
Investor Relations Contact:Email:
info@allenapharma.comPhone: 617-467-4577Fax: 617-916-1871
Allena Pharmaceuticals (NASDAQ:ALNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allena Pharmaceuticals (NASDAQ:ALNA)
Historical Stock Chart
From Apr 2023 to Apr 2024